Longeveron (LGVN) Secures Rights to Stem Cell Patent for Cardiac Treatment

Longeveron Inc. (NASDAQ:LGVN) is one of the best meme stocks. On July 21, Longeveron obtained a US patent license for stem cell technology from the University of Miami, which could help in developing treatments for heart disease.

The licensed patent (12,168,028 B2) covers a method to create GHRH-Receptor+ heart muscle cells from stem cells. These cells can develop into human heart muscle while possibly reducing the risk of ventricular arrhythmias, which has been a problem with earlier stem cell treatments.

Joshua Hare, Cofounder, Chairman, and Chief Scientific Officer of Longeveron, commented:

“This technology provides a solution to one of the most difficult barriers to the implementation of induced pluripotent stem cells technology in the cardiovascular space,”

The patented technology works by picking out cells that will become heart muscle cells and removing those that can cause electrical problems. This allows new heart tissue to form without the risk of dangerous heart rhythm issues. Longeveron believes this technology could be used to treat many heart diseases in adults and some rare conditions in children.

The company’s main experimental treatment, laromestrocel (Lomecel-B), is being developed for hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and age-related frailty. This announcement comes after Longeveron recently got IND approval for pediatric dilated cardiomyopathy.

Longeveron Inc. (NASDAQ:LGVN) is a biotech company in Miami, Florida, working on cell-based treatments for critical and age-related health conditions.

While we acknowledge the risk and potential of LGVN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LGVN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Dow 20 Stocks List: Ranked By Hedge Fund Bullishness Index and 10 Unstoppable Dividend Stocks to Buy Now.

Disclosure. None.